Grenalvon (Anagrelide)

Grenalvon is indicated for the management of a specific blood disorder characterized by elevated platelet counts. It is prescribed when platelet reduction is required to lower the risk of clot‑related complications.

• Essential thrombocythemia (primary indication)
• Adjunct therapy when platelet counts remain high despite other treatments
• Situations where rapid platelet reduction is clinically desired
• Use in patients who are candidates for cytoreductive therapy but require an oral option
• May be considered in clinical trials evaluating platelet‑lowering strategies

Side effects of Grenalvon vary in frequency and severity. Patients should be aware of both common and potentially serious reactions.

Common

• Headache
• Nausea or vomiting
• Diarrhea
• Palpitations or tachycardia
• Dizziness or light‑headedness
• Fatigue

Serious

• Severe arrhythmias
• Significant hypotension
• Pulmonary hypertension
• Hepatotoxicity (elevated liver enzymes)
• Severe bleeding events
• Allergic reactions such as rash or angioedema

Before starting Grenalvon, certain health considerations should be reviewed with a healthcare professional.

• Assess cardiovascular status, especially history of arrhythmias or heart disease
• Evaluate liver function tests prior to initiation and periodically during therapy
• Monitor complete blood count to track platelet reduction and detect cytopenias
• Use caution in patients with a history of pulmonary hypertension
• Discuss pregnancy intentions, as safety data are limited
• Adjust dose or discontinue if severe side effects develop

Grenalvon may interact with other medicines, affecting its safety or effectiveness.

Avoid

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may increase anagrelide levels
• Other antiplatelet agents or anticoagulants that could heighten bleeding risk
• Drugs that significantly lower blood pressure, potentially causing hypotension

Use with caution

• CYP3A4 inducers (e.g., rifampin, carbamazepine) which may reduce efficacy
• Beta‑blockers or other rate‑controlling agents due to additive cardiac effects
• NSAIDs, which may increase gastrointestinal irritation
• Herbal supplements such as St. John's wort that influence hepatic metabolism